Lou Yi-ping, Yan Shen-qiang, Zhang Sheng, Chen Zhi-cai, Wan Jin-ping, Lou Min
Department of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Jan;43(1):28-35. doi: 10.3785/j.issn.1008-9292.2014.01.020.
To investigate the impact of atrial fibrillation (AF) on clinical outcomes in patients with acute ischemic stroke undergoing thrombolytic therapy.
The clinical data of 330 patients with acute ischemic stroke who received intravenous recombinant tissue plasminogen activator (rt-PA) therapy in the Second Affiliated Hospital, Zhejiang University School of Medicine between June 2009 and August 2013 were reviewed. Clinical outcomes in AF and non-AF groups were evaluated by univariate and multivariate analysis. Favorable outcome was defined as a modified Rankin Scale (mRS) 0-2 on day 90. Hemorrhagic transformation (HT) was classified as hemorrhagic infarction (HI) and parenchymal hematoma (PH) within the first 24h according to ECASS II criteria. Hypoperfusion and severe hypoperfusion were defined as Tmax >6 s and >8 s, respectively. The rate of reperfusion was compared between AF and non-AF groups.
Among 330 patients, 137(41.5%) had AF. Compared with non-AF patients, patients with AF were older [(71.7±11.5)y vs (63.4±13.2)y, P<0.001], had higher baseline National Institutes of Health Stroke Scale [IQR, 13(8-16) vs 9(5-15), P<0.001], higher rate of HT(HI: 28.5% vs 17.1%, P=0.015; PH: 13.9% vs 4.1%, P=0.002), and lower rate of favorable outcome (41.5% vs 58.0%, P=0.005) at d 90. After adjustment, AF was not a risk factor for favorable outcome (OR=0.920, 95%CI:0.533-1.586; P=0.763) and mortality (OR=1.381, 95%CI:1.096-1.242; P=0.466) on day 90. AF was also not associated with HI (OR=1.676, 95%CI: 0.972-3.031; P=0.088), but it increased the rate of PH (OR=3.621, 95%CI: 1.403-9.344; P=0.008). Among 94 patients with pre- and post-thrombolytic perfusion-weighted image, AF was not associated with increased rate of reperfusion for hypoperfusion (Tmax >6 s, OR=1.12, 95%CI: 0.35-3.63, P=0.849), but was correlated with increased rate of reperfusion for severe hypoperfusion (Tmax>8 s, OR=10.57, 95%CI:1.16-96.50, P=0.037).
The presence of AF has no independent impact on neurological outcome in thrombolytic patients with acute ischemic stroke. It is associated with increased reperfusion rate of more severe hypoperfusion area and higher frequency of PH.
探讨心房颤动(AF)对接受溶栓治疗的急性缺血性脑卒中患者临床结局的影响。
回顾2009年6月至2013年8月在浙江大学医学院附属第二医院接受静脉注射重组组织型纤溶酶原激活剂(rt-PA)治疗的330例急性缺血性脑卒中患者的临床资料。通过单因素和多因素分析评估AF组和非AF组的临床结局。良好结局定义为90天时改良Rankin量表(mRS)评分为0-2分。根据ECASS II标准,出血性转化(HT)在前24小时内分为出血性梗死(HI)和脑实质血肿(PH)。将Tmax>6秒和>8秒分别定义为低灌注和严重低灌注。比较AF组和非AF组的再灌注率。
330例患者中,137例(41.5%)有AF。与非AF患者相比,AF患者年龄更大[(71.7±11.5)岁 vs (63.4±13.2)岁,P<0.001],基线美国国立卫生研究院卒中量表评分更高[四分位间距,13(8-16) vs 9(5-15),P<0.001],HT发生率更高(HI:28.5% vs 17.1%,P=0.015;PH:13.9% vs 4.1%,P=0.002),90天时良好结局发生率更低(41.5% vs 58.0%,P=0.005)。调整后,AF不是90天时良好结局(OR=0.920,95%CI:0.533-1.586;P=0.763)和死亡率(OR=1.381,95%CI:1.096-1.242;P=0.466)的危险因素。AF也与HI无关(OR=1.676,95%CI:0.972-3.031;P=0.088),但增加了PH的发生率(OR=3.621,95%CI:1.403-9.344;P=0.008)。在94例溶栓前后有灌注加权成像的患者中,AF与低灌注(Tmax>6秒)再灌注率增加无关(OR=1.12,95%CI:0.35-3.63,P=0.849),但与严重低灌注(Tmax>8秒)再灌注率增加相关(OR=10.57,95%CI:1.16-96.50,P=0.